Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6

Metastatic Nonsmall Cell Lung Cancer Clinical Trial

Official title: Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6

Status Recruiting

Clinical Trial Summary

This is a Phase I study to evaluate the safety and efficacy of the [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G theranostics pair in patients with metastatic non small cell lung cancer (NSCLC).

Clinical Trial Description

This is a Phase I study to evaluate the safety and efficacy of the [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G theranostics pair in patients with metastatic NSCLC. [68Ga]Ga DOTA-5G PET/CT will be used to identify and stratify patients eligible for (and most likely to respond to) the [177Lu]Lu DOTA-ABM-5G therapy. Up to 40 patients will be enrolled over a 36-month period with metastatic NSCLC with a life expectancy of at least 3 months, who demonstrate disease progression after at least 1 prior treatment for metastatic disease and have available archival tissue. We hypothesize that a) [68Ga]Ga DOTA-5G will detect lesions in patients with metastatic NSCLC, b) the theranostic pair [68Ga]Ga DOTA-5G/ [177Lu]Lu DOTA-ABM-5G will be safe and well tolerated, and c) a therapeutic response will be achieved with a single dose of [177Lu]Lu DOTA-ABM-5G. ;

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Metastatic Nonsmall Cell Lung Cancer

• NCT number: NCT06228482
• Study type: Interventional
• Source: University of California, Davis
• Contact: Julie L Sutcliffe, Phd
• Phone: 9167345536
• Email: jlsutcliffe@ucdavis.edu
• Status: Recruiting
• Phase: Phase 1
• Start date: January 22, 2024
• Completion date: January 2026